Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tivozanib hydrochloride by AVEO Pharmaceuticals for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...
Tivozanib hydrochloride by AVEO Pharmaceuticals for Neuroendocrine Cancer: Likelihood of Approval
Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Neuroendocrine Cancer. According to GlobalData,...
Tivozanib hydrochloride by AVEO Pharmaceuticals for Soft Tissue Sarcoma: Likelihood of Approval
Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Soft Tissue Sarcoma. According to...
Tivozanib hydrochloride by AVEO Pharmaceuticals for Gallbladder Cancer: Likelihood of Approval
Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Gallbladder Cancer. According to GlobalData,...
Tivozanib hydrochloride by AVEO Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval
Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
Tivozanib hydrochloride by AVEO Pharmaceuticals for Prostate Cancer: Likelihood of Approval
Tivozanib hydrochloride is under clinical development by AVEO Pharmaceuticals and currently in Phase II for Prostate Cancer. According to GlobalData,...